The BSX Gamble: A Tangled Web of Risk and Reward Boston Scientific's (BSX) recent struggles have sent its stock plummeting to nearly $45 a share, a 58% decline from its 52 week peak.
Investors are scrambling to make sense of the situation, with some advocating for selling cash secured put options as a way to generate immediate income while locking in an even deeper entry point.
The numbers appear appealing: selling a put option on BSX expiring in 2027 with a strike price of $30 can yield roughly $135 in premium per contract and earn about 8. 3% total cash secured return.